

AD _____

Award Number: W81XWH-11-1-0732

TITLE: Redefining the Hematopoietic Microenvironment

PRINCIPAL INVESTIGATOR: Mineo Iwata, PhD

CONTRACTING ORGANIZATION: FRED HUTCHINSON CANCER RESEARCH
SEATTLE, WA 98109-4433

REPORT DATE: April 2013

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

| REPORT DOCUMENTATION PAGE | | | Form Approved OMB No. 0704-0188 | | |
|---|------------------|-------------------------|---|---|--|
| Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. | | | | | |
| 1. REPORT DATE (DD-MM-YYYY) April 2013 | | 2. REPORT TYPE Final | | 3. DATES COVERED (From - To) 30September2011-29March2013 | |
| 4. TITLE AND SUBTITLE Redefining the Hematopoietic Microenvironment | | | 5a. CONTRACT NUMBER | | |
| | | | 5b. GRANT NUMBER W81XWH-11-1-0732 | | |
| | | | 5c. PROGRAM ELEMENT NUMBER | | |
| 6. AUTHOR(S) Mineo Iwata, PhD E-Mail: miwata@fhcrc.org | | | 5d. PROJECT NUMBER | | |
| | | | 5e. TASK NUMBER | | |
| | | | 5f. WORK UNIT NUMBER | | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) FRED HUTCHINSON CANCER RESEARCH CENTER SEATTLE WA 98109-4433 | | | 8. PERFORMING ORGANIZATION REPORT NUMBER | | |
| 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 | | | 10. SPONSOR/MONITOR'S ACRONYM(S) | | |
| | | | 11. SPONSOR/MONITOR'S REPORT NUMBER(S) | | |
| 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited | | | | | |
| 13. SUPPLEMENTARY NOTES | | | | | |
| 14. ABSTRACT <p>Hematopoietic stem cells (HSC) and their progeny reside in specialized niches of the microenvironment (ME) in the bone marrow. The ME niches control HSC self-renewal, differentiation, and maturation. The ME niche cells are derived from non-hematopoietic cells, including fibroblasts, osteoblastic and endothelial cells. Macrophages, which are hematopoietic in origin, are also a critical component of the ME niches, and can influence the function of the ME niche cells. I hypothesize that the macrophages can acquire defects that may compromise ME function and lead to bone marrow failure. To test this hypothesis, I proposed to develop a new <i>in vivo</i> model that allows the inducible depletion of the macrophages in dogs, followed by the documentation of marrow failure, and subsequent therapeutic interventions. At this period, I achieved 4 goals: (1) Optimize culture conditions for generating dog macrophages, (2) Optimize transduction efficiency of a macrophage-specific CD163 promoter construct in dog CD34+ HSC and test its macrophage-specific expression, (3) Establish a luciferase reporter assay to test the macrophage-specific promoter activity, and (4) Generate multiple lentiviral vectors containing the dog/human CD163 promoter, iCasp9, and p140MGMT constructs.</p> <p>I am currently generating a lentiviral construct that incorporates both a constitutive selectable marker (p140MGMT) that will increase the proportion of the transduced cells in marrow, and a macrophage-specific promoter that will drive the expression of an inducible suicide gene (iCasp9). The synthetic fragment of iCasp9 was annealed and cloned into p140MGMT lentiviral vector. In the original grant application, I proposed to use the CD68 promoter sequence to drive the macrophage specific expression of the inducible iCasp9 suicide gene. The CD68 promoter, however, is intronic and clones into a reverse orientation into the lentiviral vector to avoid splicing during retroviral packaging. While I attempted to clone this promoter sequence in the reverse orientation using different conditions, the cloning was not successful, likely due to the toxicity of the DNA in the bacteria. I have chosen to work with the second macrophage-specific promoter for CD163/hemoglobin scavenger receptor. The CD163 gene promoter has been reported to be macrophage specific. It is not intronic, and is located 1.4 kb region upstream of the ATG translation start site. The CD163 promoter sequences in human and canine were cloned and tested for the macrophage-specific expression by luciferase reporter assay. However, insertion of CD163 promoter constructs into the iCasp9-p140MGMT vector was not successful. I am currently constructing different combinations of synthetic promoters that were derived from transcription factor elements found in macrophage specific promoters. These synthetic promoter fragments have been proven to be effective and macrophage specific in human and mice. These constructs will be evaluated <i>in vitro</i> by luciferase reporter assays and the best construct will be cloned into a lentiviral vector to express iCasp9. Once this goal is achieved, I will make the lentiviruses on a large scale, perform an autologous transplant in two dogs using dog CD34+ cells transduced with the vector, then induce expression of the suicide gene and follow the consequences to marrow function.</p> | | | | | |
| 15. SUBJECT TERMS Hematopoietic stem cells, bone marrow failure, microenvironment | | | | | |
| 16. SECURITY CLASSIFICATION OF: | | | 17. LIMITATION OF ABSTRACT | 18. NUMBER OF PAGES 18 | 19a. NAME OF RESPONSIBLE PERSON USAMRMC |
| a. REPORT U | b. ABSTRACT U | c. THIS PAGE U | | | 19b. TELEPHONE NUMBER (include area code) |

Table of Contents

| | <u>Page</u> |
|-------------------------------------|-------------|
| Introduction..... | 4 |
| Body..... | 4 |
| Key Research Accomplishments..... | 7 |
| Reportable Outcomes..... | 8 |
| Conclusion..... | 8 |
| References..... | 8 |
| Appendices and Supporting data..... | 9 |

INTRODUCTION

Hematopoietic stem cells (HSC) and their progeny reside in specialized niches of the microenvironment (ME) in bone marrow. The ME niches control HSC self-renewal, differentiation and maturation. The cells of the ME niche are derived from non-hematopoietic cells, including fibroblasts, osteoblastic and endothelial cells. Macrophages, which are hematopoietic in origin, are also a critical component of the ME, and can influence the function of the ME niche cells. I hypothesize that the macrophages can acquire defects that may compromise ME function and lead to bone marrow failure. To test this hypothesis, I proposed to develop a new *in vivo* model that allows the inducible depletion of the macrophages in dogs, document the marrow failure, and conduct subsequent therapeutic interventions.

BODY:

Goal 1: Optimize the culture conditions for generating dog macrophages

Canine peripheral blood mononuclear cells (PBMCs) were cultured in two different media, Medium-I and Medium-II (Table 1). Medium-I was formulated and modified based on the media for human hematopoietic cells, and Medium-II was formulated based on a previous mixture used for dog hematopoietic cells (Abrams et al, 2010). Figure 1 shows that Medium-I is better for expanding dog PBMCs than Medium-II. Additionally, Figure 2 shows that the progeny of CD34+ hematopoietic stem/progenitor cells increased 4-5 fold in 7 days when cultured in the Medium-I. These data show that the Medium-I is a good choice for this study.

Next, I tested if human macrophage colony-stimulating factor (hMCSF) induces the differentiation from dog hematopoietic progenitors to macrophages. When dog PBMCs were cultured in hMCSF, 4 fold more dog macrophages than the controls were generated (magenta bars in Figure 1). When dog CD34+ (dCD34+) cells were cultured in hMCSF, more than 90% of the adherent cell population became CD163+/CD14+ macrophages (Figure 3). The macrophage number increased 10 fold in the presence of hMCSF. These data show that human MCSF is useful for generating dog macrophages *in vitro*.

Goal 2: Optimize transduction efficiency of a macrophage specific promoter construct in dog CD34+ HSC/HPC and test its macrophage-specific expression by Luciferase assay

In my initial application, I proposed to use the human CD68 promoter to drive the expression of the inducible suicide gene known as Caspase 9 (iCasp9). The GFP reporter construct under the control of CD68 promoter was originally obtained from Dr. Elaine Raines of the University of Washington (Gough and Raines, 2003). A lentiviral construct of the vector was created, and a high titer lentiviral preparation was made. Dog CD34+ cells were then transduced and cultured with hMCSF for 6 days. Figure 4 shows that the transduced cells expressed GFP and CD14+ monocyte/macrophage specific marker, assuring macrophage specific expression of the reporter construct.

However, the CD68 promoter turns out to be problematic. As I described in the Abstract, the CD68 promoter is intronic and clones into a reverse orientation in the lentiviral vector to avoid splicing during retroviral packaging. While I attempted to clone this promoter sequence in the reverse orientation using different conditions, the cloning was not successful, likely due to the toxicity of the DNA in the bacteria. I shifted my focus to work with another macrophage specific promoter for a gene called CD163/hemoglobin scavenger receptor in order to avoid the cloning issues I have had with the CD68 promoter. The CD163 gene promoter has been previously studied (Gronlund et al, 2000), and is macrophage specific. It is not intronic, and is located in the 1.4 kb region upstream of the ATG translation start site. Preparation of the human and dog CD163 promoter constructs is described in the next section of Goal 3.

I conducted optimizations for the macrophage specific constructs containing the CD163 promoter. Figure 5 shows that the U937 myelocytic leukemia line can differentiate into CD163+ macrophages by using 12-O-tetradecanoylphorbol-13-acetate (TPA). U937 cells can be transfected by using the nucleofector (Amaxa, Lonza, Cologne, Germany), and CD163 reporter activities were detected by Luciferase-based assay (GeneCopoeia, Rockville, MD) (Figure 6). These data show that the CD163 promoter constructs are functional in CD163+ cells.

Goal 3: Prepare DNA constructs containing the CD163promoter, iCasp9 and p140MGMT

I obtained the plasmid containing iCasp9 from Drs. Elizabeth Budde and Caroline Berger of the Fred Hutchinson Cancer Research Center (FHCRC) (Figure 7), and the plasmid containing p140MGMT from Dr. Hans-Peter Kiem of the FHCRC (Beard et al, 2009). The vector containing human CD163 promoter construct was purchased from GeneCopoeia. Dog and human CD163 promoters were cloned as described below.

Figure 8 shows diagrams of the lentiviral vectors. They contain the CD163promoter-iCasp9 and p140MGMT constructs. Dog and human CD163 promoters have 70% identity (Figure 9), and both promoters were

cloned into the TOPO vector (Figures 10 and 11). The iCasp9 fragment was amplified from the plasmid given by Drs. Budde and Berger as shown in Figure 11. However, as the annealing of the iCasp9 to CD163 promoter and p140MGMT vectors was not successful, I modified and optimized the iCasp9 coding region by gene sequencing (Genscript, Piscataway, NJ). The optimized synthetic fragment of iCasp9 with newly inserted NheI and MluI sites was annealed and cloned into pUC57 plasmid and the lentiviral vector of p140MGMT (Figure 12). However, attempts to clone human and dog CD163 promoter constructs into the iCasp9-p140MGMT lentiviral vector were unsuccessful.

Next I decided to modify and optimize CD163 promoter by gene synthesis. I focused on canine CD163 promoter from this point because of high sequence homology to human promoter (Figure 9). A 1.4 kb fragment of the canine genomic fragment homologous to the human CD163 promoter was synthesized (GenScript) and cloned upstream of the iCasp9fusion pUC57 plasmid using NheI and NCOI cloning sites. This entire insert of about 2.7 kb was cut with NheI and MluI. A lentiviral vector of p140MGMT was modified to include a multiple cloning sites including NheI and MluI sites. The lentiviral vector was digested with these enzymes, purified and the 2.7 kb CD163 promoter-iCasp fusion fragment was ligated to it. The colonies obtained after transformation using DH5alpha competent *E.coli* cells (BioLine) was analyzed for the recombinant plasmids. NheI-MluI double digests of the plasmid DNA from 12 different colonies did not indicate presence of the correct clones (Figure 13A).

It is possible that certain insert DNA are difficult to clone into large lentiviral constructs due to specific sequence features. To improve the chances of cloning we repeated the cloning, and used recombination deficient stab13 competent *E.coli* cells (Invitrogen) which facilitates cloning of difficult to clone inserts. Unfortunately, even using these cells there were no recombinant clones among the 16 colonies analyzed (Figure 13B). In the both of these experiments, the transformation appeared to have worked successfully, with very low level of background in the control experiments (+/- ligase), which did not receive any insert fragment. Hundreds of colonies were seen in the experimental plates (virus+insert+ligase) which upon analysis had a lentiviral size plasmid, albeit a little smaller.

The p140MGMT lentiviral vector can accept at least up to a 5 kb insert (Venkataraman, personal communication). Since the fusion DNA of CD163 promoter and iCasp9 is 2.7 kb in length, the size of DNA is not likely the problem. The DNA of iCasp9 was successfully inserted into the p140MGMT lentiviral vector, although both human and canine CD163 promoter failed to be inserted in the p140MGMT vector. These data suggest that

some DNA sequence (e.g. Alu like and other repeat elements or short nucleotide repeats) of the CD163 promoters may not be compatible with the p140MGMT vector.

Current:

Since CD68 and CD163 promoters are problematic for cloning in the p140MGMT lentiviral vector, I searched other macrophage-specific promoters previously characterized. I found a synthetic promoter (SP-146, 276 bp, GenBank Acc. # DQ107383) containing multiple transcription factor binding *cis*-elements that were derived from macrophage specific promoters. SP-146 promoter was shown to be selective for human and mouse macrophages, and its expression was much stronger than CMV-GFP and traditional macrophage specific promoters such as CD68, p47phox, CD11b and M-CSFR promoters in the lentiviral vectors (He et al 2006 and Levin et al 2012). SP-146 promoter must work in dogs, and is currently being optimized and synthesized (GenScript). Lentiviral vectors containing the SP-146 promoter-iCasp9 and p140MGMT constructs will be made. These vectors will be tested for macrophage-selective expression, and sent to the virus production core of the Core Center for Excellence of Hematology (CCEH) at the FHCRC to make the lentiviruses on a large scale for an autologous transplant in two dogs. Our virus production core would take about 2-3 weeks to make the viruses. After the viruses are produced, I will perform an autologous transplant in dogs using dog CD34+ cells transduced with the viruses, then induce expression of the iCasp9 suicide gene and follow the consequences to marrow function.

KEY RESEARCH ACCOMPLISHMENTS:

At this period of the grant support, I achieved 4 goals, as follows:

- Optimized culture conditions for generating dog macrophages
- Optimized transduction efficiency of a macrophage specific promoter construct in dog CD34+ HSC/HPC, and tested its macrophage-specific expression
- Established Luciferase-reporter assay to test the macrophage-specific promoter activity
- Constructed multiple plasmid and lentiviral vectors containing iCasp9 and p140MGMT constructs, and plasmids containing the dog/human CD163promoter as follows:

iCasp9-pUC57 plasmid

iCasp9-p140MGMT lentiviral vector

Canine CD168 promoter-pUC57 plasmid

Canine CD168 promoter-iCasp9-pUC57 plasmid

REPORTABLE OUTCOMES:

None at this grant period.

CONCLUSION:

During this period of the grant support, I have optimized the culture conditions for generating dog macrophages, and transduction of dog and human hematopoietic cells to test macrophage specific promoter activity. CD163 promoter-iCasp9 fusion pUC57 and iCasp9-p140MGMT lentiviral constructs were made. However, final construction of CD163 promoter-iCasp9-p140MGMT was not successful probably due to sequence-specific plasmid instability of the promoter. I will keep trouble-shooting the current strategy and try a synthetic macrophage-specific promoter, SP-146, instead of the CD163 promoter. Once the lentiviral vector construction is completed, the constructs will be sent to the virus production core of CCEH at the FHCRC. I will then perform an autologous transplant in dogs using dog CD34+ cells transduced with the viruses, chemoselect to increase gene marked cell frequency, then induce the macrophage specific expression of the suicide gene and follow the consequences to marrow function.

REFERENCES:

Abrams et al (2010) A novel monoclonal antibody specific for canine CD25 (P4A10): Selection and evaluation of canine Tregs. *Vet Immunol Immunopathology* 135, 257-265

Beard et al (2009) Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients. *Blood* 113, 5094-5103

Gough and Raines (2003) Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. *Blood* 101, 485-491

Gronlund et al (2000) Cloning of a novel scavenger receptor cysteine-rich type I transmembrane molecule (M160) expressed by human macrophages. *J Immunology* 165, 6406-6415

He et al (2006) Development of a synthetic promoter for macrophage gene therapy. *Human Gene Therapy* 17, 949-59

Leven et al (2012) Evaluation of macrophage-specific promoters using lentiviral delivery in mice. *Gene Therapy* 19, 1041-7

APPENDICES:
None

SUPPORTING DATA:




Figure 1

Human macrophage colony-stimulating factor (hMCSF) increases dog macrophage numbers *in vitro*. Dog bone marrow mononuclear cells (5 millions) were cultured for 7 days in the media described above, and the cell numbers were counted. The cells were analyzed using flow cytometry to identify macrophages (CD163+/CD14+ cells). The cells in Medium-I showed 2-4 fold greater expansion than those of Medium-II. From these data, hMCSF in Medium-I was chosen to be used in the following experiments.




Figure 2

Expansion cultures of dog CD34+ HSC/progenitor cells (dCD34+ cells). Dog CD34+ cells (2.5 millions) were cultured in Medium-I +/- 100ng/mL hMCSF, and the cell numbers were counted at each time point described on the X-axis. After 7 days of culture, a 3- to 5-fold expansion of the cells was achieved.




Figure 3

***In vitro* generation of canine macrophages from dCD34⁺ cells.** dCD34⁺ cells were cultured in Medium-I in the presence and absence of hMCSF (100 ng/mL) for 7 days. The cells were harvested and analyzed for CD14 and CD163 expression by using flow cytometry (panel A). Macrophages are defined as CD163 bright/CD14 bright cells in the upper right quadrant. In the presence of hMCSF, all of the cells differentiated to macrophages. Panel B shows the number of macrophages at Day 7. Panels C and D show phase-contrasted images of the cells cultured in the absence and presence of hMCSF, respectively. The images were captured with an inverted microscope using the X20 objective.




Figure 4

Macrophage specific expression of the CD68 promoter-GFP construct. dCD34+ cells were infected with the lentivirus containing GFP driven by the CD68 promoter. The cells were cultured in Medium-I in the presence of 100 ng/mL of hMCSF for 6 days, and stained for CD14 (red). **Panel A:** Arrows indicate the infected cells (GFP+) co-expressing CD14. Asterisks indicate uninfected CD14+ monocytes/macrophages. (X40 objective) **Panels B-E:** Images taken with a high magnification (X100 objective) of the same specimen as in Panel A are shown. The cell on the left (L) is an uninfected CD14+ monocyte/macrophage. The cell in the center (C) is uninfected and non-myeloid. The cell on the right (R) is an infected monocyte/macrophage (GFP+/CD14+). Panel B shows GFP, Panel C CD14 (red), Panel D nucleus (blue), and Panel E is combined.




Figure 5

The phorbol ester, 12-o-tetradecanoylphorbol-13-acetate (TPA), induces differentiation of U937 cells (human myelocytic cell line) to CD163+ macrophage-like cells. U937 and HL-60 (human promyelocytic leukemia line) cells were cultured in the absence and presence of 100ng/mL TPA for 3 days. Surface expression of CD163 was determined by using flow cytometry. More than 20% of U937 cells became CD163+ after TPA stimulation. HL-60 cells, in contrast, did not change CD163 expression after TPA stimulation.




Figure6

Transduction of U937 cells with pMac-GFP and HPRMCD163 plasmids. U937 cells were transfected with pMac-GFP and HPRM-CD163 plasmids by nucleofection (Nucleofector II, using the program W-01) in the nucleofection solution with supplement in the Kit C (Amaxa). After 6 hours of culture, GFP expression of the untransduced (panel A) and transduced (panel B) cells was measured by using flow cytometry. More than 30% of the cells were transduced and express GFP. Panel C shows Luciferase reporter assay. The cells were stimulated with 50 ng/mL of TPA and harvested at the time point indicated in X axis. CD163 promoter activities were detected by Luciferase assay (Secreta-Pair Dual Luminescence Assay Kit, GeneCoproiea).




Figure 7.

Schematic diagram of the vector containing iCasp9 suicide gene. Gifted from Dr. Elizabeth Budde at the FHCRC.




Figure 8.

Schematic representation and vector map of the lentiviral vector. The constitutive EF1 promoter drives the expression of p140MGMT which will be used for *in vivo* selection. The tissue specific CD163 promoter will drive the expression of the suicide gene (iCasp9), which can be activated after the administration of the small molecule chemical inducer of dimerization (AP20187, Ariad Pharmaceuticals). The woodchuck post-transcriptional regulatory element (WPRE) is included in the construct to enhance expression of the tissue specific suicide gene.

Score = 581 bits (644), Expect = 1e-169 Identities = 927/1322 (70%), Gaps = 110/1322 (8%)

| | | | |
|-------|-----|--|-----|
| Cf163 | 182 | AATCCTCA-ATGTACAGGTTGCCATGAGTGCACAGTTTCTGGAATAATTCAAGGTTCAAG | 240 |
| | | | |
| Hs163 | 154 | AACCCCTCATAAGTACAGGCTATCATGAGTGCATATTTCTGGGGTCTTTCAGCGTTAGAG | 213 |
| Cf163 | 241 | TTATTTTACCTAGTGAAGTCGTGTTTAACCAAAGACATAAAAGACAGAAGACTAAGAG-- | 298 |
| | | | |
| Hs163 | 214 | TTATTTCTCCTAGTGAAGGAGGTTTAACTGA-GAAATAAAGTATATGTGAGTGAGAGTT | 272 |
| Cf163 | 299 | --CTCAG-GAAGGACAGTGGCAGAAAGT-AGTACACACAAAAGGAACAATGTGTGTAA-- | 352 |
| | | | |
| Hs163 | 273 | ATCTTAGAGAAAGGTACGGGTAGGGAGGCAGTAAACACAGAAGGAACAATATGTATGACA | 332 |
| Cf163 | 353 | -----GAGGTTAGTCGTGTCCAAGGAATAGAAAGAAGCCAGAGTGACCT | 396 |
| | | | |
| Hs163 | 333 | TACCATGAGGCAGGAGAGATTTGGCATGCCCAGAAAGTGAAGAAAAGTGGGGTGCCTT | 392 |
| Cf163 | 397 | TTTTCACTGGATTATAGTGAAGTGTCTCCTTGCAAGACTGGAGATGCTTCTTAAACTCCCC | 456 |
| | | | |
| Hs163 | 393 | TGTTGACTGGGTTCTAGTGAATGTCTCTCTGGAAGGCTGGAGTTGCT-CTTTAATTCCCC | 451 |
| Cf163 | 457 | CTT-CTGGCGCACCCTATTACCAGAGAATGTTTATCCCATCAGGGACCATC----- | 507 |
| | | | |
| Hs163 | 452 | ATTTTCAGGCCCATCACTAACACCTGACAATATGTATGCCATGATGAACCTATTAGTAGTTC | 511 |

```

Cf163  508  ----GAATTTCCATGTTTTTACATGCCTGTATTGTTGGTATATGtcttttcttatactt 563
      || || ||||| || | ||| || ||| || ||| ||| |||
Hs163  512  TTTTGAGCTTATATGTTTTATATACAAATATTCATTTGTATGTG-CTATTTTATGCCT 570

Cf163  564  taaatatattttatcttttttc--tttGGGGGCAAAGTC---CTCATTATTTAGGACACAA 618
      |||| ||||| || | |||| || || |||| ||||| |||||
Hs163  571  TAAACTCCTTTATCATTTGTCCCTTGG---CAATGTTTTTCTCATCTTTTAGGACACAA 627

Cf163  619  TTTAAGCACCTTCTCACAGAAAAGAGTTTTCTGACTATTCATTTCTGTCTCCAGTTGAT 678
      ||||| || |||| ||||| ||||| ||||| ||||| ||||| |||
Hs163  628  TTTAAGCCTGTCTCAGAGAAAATAGTTTTCTGACTGTTCAATTCCTTTCTCTCAATAGAT 687

Cf163  679  ATGACCTGTTTTTCTTTATTTTTCTACTCTGTGCTTGAATCGCTCTGGATTATTGCTCA 738
      | ||| || || ||||| || || |||| | || | ||| ||| |
Hs163  688  AGGACTACTTTGTCCATTATTTTAACTGCACCTTAGCTTTATGTTTCATTGTTGTTAT 747

Cf163  739  CRATGTGTTTCTTTTCACT-GAATTTGAGTTATTCAGAGCTAAAATTACGTCTTATAAAT 797
      | ||||| ||||| || || |||| |||| ||||| || || |||
Hs163  748  CATATGTGTTTCTCTTACTTGAATCTGANTTATATGGAGCTAAAATCATGTGTTGCTAAT 807

Cf163  798  TTTTATTGCACCATTTGTAGAATCTGTAATGGTCATGGCTAATTTTATTGTTACTCTTCA 857
      |||| | ||||| |||| ||||| ||||| ||||| ||||| |||||
Hs163  808  TTTTGTTCACCATTTGTAATATCAGTAATAGTCATGGCTAATCTCTTGGTGTACTTCA 867

Cf163  858  TCTCATTAGAAAAGAGAAAGCAAATGCCTTCTGTAGATGGTCTACACAAAATTATTCATT 917
      || ||||| ||||| || ||||| || || ||||| ||||| |||||
Hs163  868  TCCCATTAGAAAAGAAATGACAAATGCTGTGTCTCAACAACCTTACACAAAATTACTCATT 927

Cf163  918  CAGCTCATTTGATTATGGTAATAGTATTAAAAGTGATGAACTGATAAAACATTATTTAA 977
      | ||||| ||||| |||| ||||| || || ||||| ||||| |||||
Hs163  928  ANACACATTTGATTATGGAATAAAATTTAAAG---TGCATATGATAAAATGTTATTTAA 984

Cf163  978  TTATGTTTTGCTTATTTTCACTTTAGTTTTTGTACATAA---CTGCACAGTGA---TAGTC 1030
      ||||| ||||| || || ||||| ||||| || || |||| |||||
Hs163  985  TTATGTTTTGCCTGTTTTGCTTTAGTTTTTACATAATTTTCTACA-TGACAATTAGTA 1043

Cf163  1031 A-TTTTTATTCTAATATATTACTCCAAAACAAAGTATGGAAATCT-AAATATTCATTTTC 1088
      | |||| | || ||||| ||||| |||| ||||| ||||| |||||
Hs163  1044 ATTTTTTGTGTCTTATATATTTGTCCAAAATGAAGTTCAAAAATGTAAAATATTTAATTC 1103

Cf163  1089 AATAGCAACGGAACATGCATTAGTATTTCCCTTAATTTTGTAAATCTGT---AGTGT 1144
      | | || | || ||||| ||||| ||||| ||||| ||||| |||||
Hs163  1104 AGCAACAGCAGCATATGAGTTAGTATTTCTCTC-TAATTTTTCGAAATCTGTGGGAAGTGT 1162

Cf163  1145 TTCTCAATTTCTTTTGGTTGTTTCATGTCCCAAATGAAGAAAACATGAGTATGAAAGGG 1204
      ||| ||||| ||||| ||||| || ||||| ||||| ||||| |||||
Hs163  1163 TTCCCAATTTCTTTGGTTGTTTCATGTGCTATATGAAGAAAACATGAGTATGAAATGG 1222

Cf163  1205 AACCTCAG-TTTGTGAATGACTTCCCTTTTTTCGTTGATTGACTCCACCTCCTTTATGTA 1263
      ||||| || | ||||| ||||| || ||||| ||||| ||||| |||||
Hs163  1223 AACCTCAGCTCTTTCAATGACTTCCCTTTTTGAG---TTGACTCCGCCTCC-ATATGTA 1277

Cf163  1264 GCCTTCTGGGGTTTTCTGTGTGTTTTGCTTTGCTTTGTCTTGTGGAATGAGATGATT 1323
      ||| |||| || || || || || || || || || || || || ||
Hs163  1278 GCC-----TTTTCATTT-----TCATGAAAGTGAAGTGAAT 1308

Cf163  1324 TTTAGAATTCTTAGTGGTCCTCTTTAGCAGAACACTTCTAAGGAATAATACAAGAAGATT 1383
      ||||| ||||| || ||||| ||||| ||||| ||||| ||||| |||||
Hs163  1309 TTTAGAATTCTTAGTTGTTTCTTTAGAAGAACATTTCTAGGGAATAATACAAGAAGATT 1368

Cf163  1384 TAGAAATCATTAATACTCTGGACTGGACAAACTCAGCTCCAGATCT 1429
      ||| ||||| || || || || || || || || || || || || ||
Hs163  1369 TAGGAATCATTGAAGTTAT-----AAATCTTTGGCTCCAGATCT 1407

```

Figure 9.
Comparison of Dog CD163 promoter to Human CD163 promoter. 1.4kb upstream of the non-coding promoter region before ATG translation start site was aligned between dog (Cf) and human (Hs). The CD163 promoter from human is shown to be specific for macrophages (Gronlund et al 2000). The dog CD163 promoter has 70% identity to the human promoter.




Figure 10

Cloning of human and dog CD163 promoters by PCR from genomic DNA. Human and dog genomic DNAs were PCR-amplified using the primers described in Table 2. The PCR conditions were 95°C/5 min, followed by 35 cycles of 98°C/10 sec, 58°C-64°C step gradient/45 sec and 72°C/1 min in GC buffer (BioLine) with Velocity DNA polymerase (BioLine). PCR products were cloned into the TOPO cloning vector (Invitrogen). Restriction digests of 8 clones for both species are shown. The arrowheads indicate the position of the promoters.




Figure 11

PCR amplification of CD163 promoters and iCasp9 construct. Lane 1: dog CD163 promoter. Lane 2: human CD163 promoter. Lane 3: iCasp9 construct. The arrow indicates the position of the CD163 promoters (14 kb), and the arrowhead indicates the position of the iCasp9 (12 kb). M.W. stands for molecular weight markers (BioLine Hyperladder II, 50 bp to 2000 bp). MiFi taq polymerase (BioLine) was used. PCR conditions were 95°C/5 min, and then 35 cycles of 98°C/10 sec, 62°C/45 sec and 72°C/1 min.



Figure 12

Restriction enzyme digestion of the plasmids containing the optimized synthetic iCasp gene. The optimized iCasp construct was designed and commercially synthesized (Genscript). The construct was cloned into p140MGMT lentiviral vector after cutting with EcoRI. Thirty clones were picked up and digested with BamHI and Nhe I to identify clones containing the insert with the correct orientation. Three such clones are indicated by asterisks. The clones were confirmed by sequencing. Hyper Ladder I and II (BioLine) were used to determine the molecular weights.




Figure 13

Restriction enzyme digestion of the transformants for the final constructs containing the canine CD163 promoter-iCasp9-p140MGMT. The colonies obtained after transformation using DH5alpha (BioLine, Panel A) or Stbl3 (Invitrogen, Panel B) competent *E.coli* cells were analyzed for the recombinant plasmids. NheI-MluI double digests of the plasmid DNA from 12-16 different colonies did not indicate presence of the correct clones with the 2.7 kb insert (arrows). p140MGMT vector without any insert is about 7 kb in size. M.W., molecular weight markers (Hyper Ladder I, BioLine).

Table 1. Culture media used for dog hematopoietic cells.

| Medium-I | | Medium-II | |
|----------------------------------|-----------|----------------------------------|--------|
| Iscove's medium | 500 mL | Iscove's medium | 450 mL |
| FCS | 50 mL | Waymouth's medium | 450 mL |
| Penicillin/Streptomycin solution | 5 mL | Dog serum | 100 mL |
| Glutamine, 200 mM | 5 mL | Penicillin/Streptomycin solution | 10 mL |
| Sodium pyruvate, 100 mM | 5 mL | Glutamine, 200 mM | 10 mL |
| human IL-3 | 200 ng/mL | Sodium pyruvate, 100 mM | 10 mL |
| human IL-6 | 100 ng/mL | Non-essential amino acids | 10 mL |
| human SCF | 100 ng/mL | | |
| human Flt3-L | 100 ng/mL | | |
| dog G-CSF | 100 ng/mL | | |
| human TPO | 100 ng/mL | | |

Table 2. Primers used in this study

| Name | | Size (bp) | Sequence* |
|----------------------|---|-----------|--|
| Human CD163 promoter | F | 36 | CCA GGT ACC GCT AGC <u>AGC ACA CCA GCA TTG CAC ATG</u> |
| | R | 40 | CCA AGA TCT <u>CGA GCC AAA GAT TTA TAA CTT CAA TGA TTC C</u> |
| Dog CD163 promoter | F | 40 | CCA GGT ACC GCT AGC <u>CAA GTG CTA TCC GCA AGG GCT GGT G</u> |
| | R | 34 | CCA AGA TCT <u>CGA GCT GAG TTT GTC CAG TCC AGA G</u> |
| iCASP | F | 29 | ATGGGAGTGCAGGTGGAACCATCTCCCC |
| | R | 35 | GCT CGA GCG GCC GCT CTT ATG ATG TTT TAA AG |

* Underbar shows the unmodified sequence from the promoter.